Home » Stocks » MDNA

Medicenna Therapeutics Corp. (MDNA)

Stock Price: $3.21 USD -0.13 (-3.89%)
Updated May 13, 2021 3:30 PM EDT - Market open
Market Cap 183.13M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 52.90M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $3.21
Previous Close $3.34
Change ($) -0.13
Change (%) -3.89%
Day's Open 3.34
Day's Range 3.18 - 3.39
Day's Volume 83,569
52-Week Range 3.14 - 6.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

-- Data published in Clinical Cancer Research indicate that early determination of PFS with modified RANO criteria may be a strong surrogate for overall survival in recurrent glioblastoma

6 days ago - GlobeNewsWire

TORONTO and HOUSTON, April 21, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...

3 weeks ago - GlobeNewsWire

TORONTO and HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...

4 weeks ago - GlobeNewsWire

-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages

Other stocks mentioned: MDNAF
1 month ago - GlobeNewsWire

-- MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model

1 month ago - GlobeNewsWire

TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...

Other stocks mentioned: MDNAF
2 months ago - GlobeNewsWire

TORONTO and HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced tha...

Other stocks mentioned: MDNAF
2 months ago - GlobeNewsWire

TORONTO and HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced tha...

Other stocks mentioned: MDNAF
2 months ago - GlobeNewsWire

TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its fi...

Other stocks mentioned: MDNAF
3 months ago - GlobeNewsWire

TORONTO and HOUSTON, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced today th...

4 months ago - GlobeNewsWire

About MDNA

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
MDNA
Full Company Profile

Financial Performance

Financial Statements